Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
PR Newswire —
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch of Inpefa® (sotagliflozin) in the United Arab Emirates (UAE), the first...